On Monday, Silence Therapeutics plc (NASDAQ: SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback